Sun denies Ranbaxy deal insider trading suggestions
This article was originally published in Scrip
Executive Summary
Sun Pharma had moved swiftly to clarify that it has not violated insider trading rules, amid suggestions that India's markets regulator may consider a preliminary probe into the significant spike in Ranbaxy's shares on local bourses ahead of its acquisition by Sun.
You may also be interested in...
Sun US Chief Gandhi Settles Insider Trading Case
Top Sun Pharma executive Abhay Gandhi and his wife have settled a case pertaining to alleged insider trading in shares of Ranbaxy around the time of the company’s acquisition by Sun from Daiichi Sankyo in 2014. Sun, which has been firefighting a raft of governance concerns, has vouched for the executive’s integrity.
Sun US Chief Settles Insider Trading Case
Top Sun Pharma executive Abhay Gandhi and his wife have settled a case pertaining to alleged insider trading in shares of Ranbaxy around the time of the company’s acquisition by Sun from Daiichi Sankyo in 2014. Sun, which has been firefighting a raft of governance concerns, has vouched for the executive’s integrity.
Sun Claims It Played By Rulebook As Corporate Governance Allegations Smoulder
Sun Pharma, which has been hit by allegations of grave lapses in corporate governance practices, has given its side of the story, essentially emphasizing that it has done no wrong. The company, however, signaled that it is open to reviewing certain operational arrangements should that improve investor confidence.